
Supplemental Data to *Drug Metabolism and Disposition*

**Multi-omics profiling reveals protective function of *Schisandra* lignans
against acetaminophen-induced hepatotoxicity**

Caixia Yan^{1a}, Huimin Guo^{1a}, Qingqing Ding^{1b}, Yuhao Shao^a, Dian Kang^a, Tengjie Yu^a, Changjian Li^a,
Haoran Huang^a, Yisha Du^a, He Wang^a, Kangrui Hu^a, Lin Xie^a, Guangji Wang^{**a}, Yan Liang^{*a}

a. Key Lab of Drug Metabolism & Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Tongjiaxiang 24, Nanjing 210009, P.R. China

b. Department of Geriatric Oncology, First Affiliated Hospital of Nanjing Medical University (Jiangsu People's Hospital), No. 300 Guangzhou Road, Nanjing 210029, P.R. China

* Corresponding author. Tel.: +86 25 83271060; fax: +86 25 83271060;

E-mail addresses: liangyan0679@163.com; guangjiwang@hotmail.com

¹ These authors contributed equally to this work.

Captions of Supplemental Figures and Tables

Table S1 The contents of schizandrol A, schizandrol B, schisantherin A, schizandrin A, schizandrin B in SLE.

Table S2 The primer sets for the target genes.

Figure S1 The effect of SLE on liver pathological sections (A), intrahepatic ALT (B) and AST (C) of mice via intragastric administration of SLE (500 mg/kg) twice a day for 3 consecutive days.

Table S3 Metabolism pathways of APAP induced hepatotoxicity and hepatoprotective effect of SLE.

Table S4 Fold change of DAGs in APAP-induced liver injury and SLE-treated mice.

Table S5 Fold change of TAGs in APAP-induced liver injury and SLE-treated mice.

Table S1 The contents of schizandrol A, schizandrol B, schisantherin A, schizandrin A, schizandrin B in SLE.

Schisandra Lignans	Content (%)
Schizandrol A	0.047
Schizandrol B	0.397
Schisantherin A	4.610
Schizandrin A	7.670
Schizandrin B	0.019

Table S2 The primer sets for the target genes.

	Forward	Reverse
FASN	GGAGGTGGTGATAGCCGGTAT	TGGGTAATCCATAGAGCCCAG
DGAT2	TGGGTCCAGAAGAAGTTCAGAAGTA	ACCTCAGTCTCTGGAAGGCCAAAT
ACC1	AATGAACGTGCAATCCGATTTG	ACTCCACATTTGCGTAATTGTTG
CD36	GAACCACTGCTTTCAAAAAGTGG	TGCTGTTCTTTGCCACGTCA
PKC α	CAAGGGATGAAATGTGACACC	CCTCTTCTCTGTGTGATCCATTC
PKC β	CCTCGGGAAGCAGAAAAGTAAC	TCCATACTGAGTTTTGGTGGAG
PKC γ	GTCGACTGGTGGTCTTTTGG	CTCATCTTCCCATCAAAGG
PKC δ	CAAGAAGAACAACGGCAAGG	TGCACACACATCAGCACCT
PKC θ	GGCCAAGGACCTTCTAGTGA	TCCCAGTTGATCTCTCGAAAC
ACC2	CCTTTGGCAACAAGCAAGGTA	AGTCGTACACATAGGTGGTCC
FATP5	GACCACTGGACTCCCAAAGC	GACAGCACGTTGCTCACTTGT
L-FABP	CCATGAACTTCTCCGGCAAGTACC	CTTTGGGTCCATAGGTGATGGTGAG




Figure S1 The effect of SLE on liver pathological sections (A), intrahepatic ALT (B) and AST (C) of mice via intragastric administration of SLE (500 mg/kg) twice a day for 3 consecutive days.

Table S3 Metabolism pathways of APAP induced hepatotoxicity and hepatoprotective effect of SLE

	Total	Hits	P value
Urea Cycle	25	8	3.28E-07
Ammonia Recycling	27	7	9.90E-06
Arginine and Proline Metabolism	47	8	5.86E-05
Purine Metabolism	66	9	0.000115
Glutamate Metabolism	44	7	0.000291
Alanine Metabolism	13	4	0.000508
Malate-Aspartate Shuttle	8	3	0.001502
Aspartate Metabolism	30	5	0.00197
Gluconeogenesis	32	5	0.002659
Glucose-Alanine Cycle	10	3	0.003079
Nicotinate and Nicotinamide Metabolism	34	5	0.003509
Phenylalanine and Tyrosine Metabolism	21	4	0.003545
Glutathione Metabolism	22	4	0.004235
Selenoamino Acid Metabolism	26	4	0.007905
Galactose Metabolism	33	4	0.018465
Glycine and Serine Metabolism	52	5	0.02167
Phenylacetate Metabolism	8	2	0.024684
Lactose Degradation	9	2	0.031107
Glycolysis	23	3	0.034205
Cysteine Metabolism	23	3	0.034205
Starch and Sucrose Metabolism	26	3	0.047052

Table S4 Fold change of DAGs in APAP-induced liver injury and SLE-treated mice

Name	Formula	Mass	A vs C	P value	AS vs A	P value	AS vs C	P value
DAG(12:0/18:2/0:0)	OHC ₃₃ H ₅₉ O ₄	554.4735	2.99	0.01	0.68	0.13	2.03	0.02
DAG(16:1/16:0/0:0)	OHC ₃₅ H ₆₅ O ₄	584.5226	2.29	0.01	0.33	0.00	0.76	0.14
DAG(16:0/18:1/0:0)	OHC ₃₇ H ₆₉ O ₄	612.5531	2.42	0.01	0.30	0.00	0.73	0.14
DAG(16:0/18:2/0:0)	OHC ₃₇ H ₆₇ O ₄	610.5386	3.14	0.02	0.37	0.01	1.16	0.56
DAG(16:1/18:2/0:0)	OHC ₃₇ H ₆₅ O ₄	608.5213	3.61	0.01	0.38	0.01	1.37	0.32
DAG(18:0/18:1/0:0)	OHC ₃₉ H ₇₃ O ₄	640.5865	1.52	0.05	0.55	0.02	0.84	0.18
DAG(18:1/18:1/0:0)	OHC ₃₉ H ₇₁ O ₄	638.5703	3.13	0.05	0.30	0.02	0.94	0.64
DAG(18:1/18:2/0:0)	OHC ₃₉ H ₆₉ O ₄	636.5556	6.00	0.02	0.27	0.01	1.62	0.01
DAG(18:2/18:2/0:0)	OHC ₃₉ H ₆₇ O ₄	634.5397	4.20	0.05	0.35	0.04	1.47	0.05
DAG(18:2/18:3/0:0)	OHC ₃₉ H ₆₅ O ₄	632.5227	3.84	0.03	0.34	0.04	1.31	0.31
DAG(18:2/18:4/0:0)	OHC ₃₉ H ₆₃ O ₄	630.5104	3.53	0.05	0.34	0.04	1.20	0.41
DAG(18:1/20:1/0:0)	OHC ₄₁ H ₇₅ O ₄	666.6028	1.05	0.84	0.33	0.00	0.35	0.02
DAG(18:2/20:1/0:0)	OHC ₄₁ H ₇₃ O ₄	664.5855	2.07	0.01	0.31	0.00	0.64	0.03
DAG(18:0/20:4/0:0)	OHC ₄₁ H ₇₁ O ₄	662.5696	1.77	0.04	0.62	0.03	1.10	0.62
DAG(18:1/20:4/0:0)	OHC ₄₁ H ₆₉ O ₄	660.5528	2.64	0.04	0.45	0.03	1.19	0.55
DAG(16:0/22:6/0:0)	OHC ₄₁ H ₆₇ O ₄	658.5382	1.61	0.01	0.81	0.18	1.30	0.38
DAG(18:2/20:5/0:0)	OHC ₄₁ H ₆₅ O ₄	656.5233	2.87	0.06	0.50	0.16	1.44	0.09
DAG(18:1/20:4/0:0)	OHC ₄₃ H ₇₃ O ₄	688.5881	1.31	0.32	0.66	0.09	0.86	0.18
DAG(18:0/22:6/0:0)	OHC ₄₃ H ₇₁ O ₄	686.5698	2.14	0.02	0.86	0.50	1.84	0.03
DAG(18:1/22:6/0:0)	OHC ₄₃ H ₆₉ O ₄	684.5538	3.15	0.05	0.36	0.03	1.13	0.59
DAG(18:2/22:6/0:0)	OHC ₄₃ H ₆₇ O ₄	682.5379	4.75	0.03	0.48	0.04	2.28	0.03

Table S5 Fold change of TAGs in APAP-induced liver injury and SLE-treated mice

Name	Formula	Mass	A vs C	P value	AS vs A	P value	AS vs C	P value
TAG 42:1	C ₄₅ H ₈₄ O ₆	720.6268	2.49	0.03	0.89	0.62	2.22	0.03
TAG 44:1	C ₄₇ H ₈₈ O ₆	748.6581	2.14	0.00	0.68	0.02	1.46	0.01
TAG 44:2	C ₄₇ H ₈₆ O ₆	746.6424	6.77	0.02	0.94	0.84	6.36	0.02
TAG 46:1	C ₄₉ H ₉₂ O ₆	776.6894	3.17	0.01	0.56	0.04	1.78	0.02
TAG 46:2	C ₄₉ H ₉₀ O ₆	774.6737	7.23	0.01	0.71	0.26	5.13	0.01
TAG 48:1	C ₅₁ H ₉₆ O ₆	804.7207	3.11	0.00	0.59	0.10	1.83	0.02
TAG 48:2	C ₅₁ H ₉₄ O ₆	802.705	6.25	0.03	0.37	0.09	2.31	0.03
TAG 48:3	C ₅₁ H ₉₂ O ₆	800.6894	6.85	0.01	0.46	0.05	3.15	0.02
TAG 50:1	C ₅₃ H ₁₀₀ O ₆	832.752	1.96	0.03	0.60	0.07	1.18	0.11
TAG 50:2	C ₅₃ H ₉₈ O ₆	830.7363	2.41	0.01	0.55	0.04	1.33	0.09
TAG 50:3	C ₅₃ H ₉₆ O ₆	828.7207	3.53	0.01	0.42	0.03	1.48	0.04
TAG 50:4	C ₅₃ H ₉₄ O ₆	826.705	4.57	0.01	0.48	0.06	2.19	0.03
TAG 50:5	C ₅₃ H ₉₂ O ₆	824.6894	5.63	0.00	0.65	0.13	3.66	0.01
TAG 52:4	C ₅₅ H ₉₈ O ₆	854.7363	1.33	0.04	0.80	0.04	1.06	0.14
TAG 52:5	C ₅₅ H ₉₆ O ₆	852.7207	2.83	0.00	0.74	0.20	2.09	0.03
TAG 52:6	C ₅₅ H ₉₄ O ₆	850.705	3.41	0.01	0.65	0.15	2.22	0.03
TAG 52:7	C ₅₅ H ₉₂ O ₆	848.6894	4.60	0.01	0.71	0.25	3.27	0.02
TAG 52:8	C ₅₅ H ₉₀ O ₆	846.6737	4.27	0.01	0.86	0.56	3.67	0.02
TAG 54:3	C ₅₇ H ₁₀₄ O ₆	884.7833	2.01	0.00	0.73	0.07	1.47	0.05
TAG 54:4	C ₅₇ H ₁₀₂ O ₆	882.7676	1.65	0.01	0.74	0.03	1.22	0.09
TAG 54:5	C ₅₇ H ₁₀₀ O ₆	880.752	1.66	0.02	0.78	0.07	1.29	0.08
TAG 54:6	C ₅₇ H ₉₈ O ₆	878.7363	2.04	0.03	0.93	0.71	1.90	0.03
TAG 54:7	C ₅₇ H ₉₆ O ₆	876.7207	1.93	0.01	0.87	0.57	1.68	0.02
TAG 56:6	C ₅₉ H ₁₀₂ O ₆	906.7676	1.68	0.02	1.11	0.55	1.86	0.02
TAG 58:8	C ₆₁ H ₁₀₂ O ₆	930.7676	1.84	0.04	1.12	0.46	2.06	0.02